摘要
自美国INTO116试验结果发表以后,胃癌术后辅助治疗已经成为局部晚期胃癌的标准治疗方法,但对胃癌术前新辅助治疗的价值,目前还未能达成共识。现临床有大量研究显示:通过术前新辅助治疗,不仅可以提高患者的R0切除率,还可以减少复发转移,提高患者生存期,该文就目前国内外关于进展期胃癌术前新辅助治疗的进展进行综述。
Since the results of INTOII6 trial was published in US, postoperative adjuvant therapy has become a standard treatment of locally advanced gastric cancer, however,there is still no consensus on its clinical value for gastric cancer. Clinical researches have shown that preoperative neoadjuvant therapy can increase R0 resection rate, reduce the recurrence and metastasis, and improve overall survival of patients. This paper summarized the progress in the preoperative neoadjuvant treatment for advanced gastric cancer.
出处
《中国肿瘤》
CAS
CSCD
2017年第7期544-549,共6页
China Cancer
关键词
胃癌
新辅助放疗
新辅助化疗
gastric cancer
neoadjuvant radiotherapy
neoadjuvant chemotherapy
